Adherence to patient selection criteria in patients undergoing transcatheter aortic valve implantation with the 18F CoreValve ReValving System
- 10 September 2009
- Vol. 96 (1), 19-26
- https://doi.org/10.1136/hrt.2009.172809
Abstract
Background: Anecdotal evidence suggests that transcatheter aortic valve implantation (TAVI) is being used beyond pre-market label indications. Methods: To assess the frequency and outcomes associated with “off-label” use of TAVI, we conducted a retrospective study, examining adherence to patient selection criteria in 63 patients undergoing implantation with the 18F CoreValve ReValving System (CRS). Label status (on-label vs off-label) was determined by following (1) inclusion/exclusion criteria indicated in the 18F CRS safety and efficacy trial and (2) a patient selection matrix indicating anatomical boundaries to guide patient selection. Off-label use was defined as the presence of at least one exclusion criterion or “non-acceptable” criteria based on the patient selection matrix. Results: Off-label implantation was identified in 42 patients (67%)—40% had one, 19% had two and 8% had three or more off-label criteria. Baseline demographics were similar between the groups except for a higher logistic EuroSCORE in the on-label group (19.8 (11.2) vs 14.5 (7.3), p = 0.029). There was no significant difference in the procedural success rates between the on-label and off-label groups (91% vs 95%, respectively, p = 0.47). The frequency of angiographic moderate-severe aortic regurgitation, post-implant dilatation or implantation of a second valve was also similar between the groups. At 30 days, the cumulative death rate was 10%; there were four deaths in the “on-label” and three deaths in the “off-label” group. Conclusion: In this study we found that “off-label” implantation of the CRS was common. Further studies are needed to evaluate the consequences of “label status” for patients undergoing TAVI.Keywords
This publication has 26 references indexed in Scilit:
- Progress and Current Status of Percutaneous Aortic Valve Replacement: Results of Three Device Generations of the CoreValve Revalving SystemCirculation: Cardiovascular Interventions, 2008
- Implantation of two self‐expanding aortic bioprosthetic valves during the same procedure—Insights into valve‐in‐valve implantation (“Russian doll concept”)Catheterization and Cardiovascular Interventions, 2008
- Trans-catheter aortic valve implantation in the United Kingdom: NICE guidanceHeart, 2008
- Anatomy of the Aortic Valvar Complex and Its Implications for Transcatheter Implantation of the Aortic ValveCirculation: Cardiovascular Interventions, 2008
- Overestimation of aortic valve replacement risk by EuroSCORE: implications for percutaneous valve replacementEuropean Heart Journal, 2008
- A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label IndicationsThe New England Journal of Medicine, 2008
- Malfunctions and Adverse Events Associated With Off-Label Use of Biliary Stents in the Peripheral VasculatureClinical Journal of Sport Medicine, 2008
- Long-Term Follow-Up of Drug-Eluting Stents When Inserted for On- and Off-Label IndicationsThe American Journal of Cardiology, 2007
- On- Versus Off-Label Use of Drug-Eluting Coronary Stents in Clinical Practice (Report from the American College of Cardiology National Cardiovascular Data Registry [NCDR])The American Journal of Cardiology, 2006
- Should PFO closure devices be used “off label”?Catheterization and Cardiovascular Interventions, 2002